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The oxidative stress theory of atherosclerosis is based on the concept that reactive oxidant species (ROS) gener-
ated by monocytes–macrophages and endothelial cells con-
tribute to initiation of atherosclerotic process via oxidation of 
low-density lipoprotein.1,2 Thus, ROS generated by enzymes, 
including myeloperoxidase, xanthine-oxidase, and NADPH 
oxidase, appear to be implicated in atherosclerosis.3,4 Studies 
conducted in human atherosclerotic plaque demonstrated that 
NADPH oxidase is overexpressed and predominantly contrib-
utes to vascular oxidative stress.5 Also, experimental studies 
demonstrated that the functional deficiency of NADPH oxi-
dase is associated with reduced inflammation and atheroscle-
rotic lesion.6–8 However, it remains to be clarified whether 
ROS derived from NADPH oxidase have some role in the pro-
cess of human atherosclerosis.
Chronic granulomatous disease (CGD) is a very rare 
genetic disorder9,10 (1:250 000 individuals)11 characterized by 
life-threatening infectious diseases.12 It is characterized by 
defective activity of the innate immune system, caused by 
functional deficiency of NADPH oxidase subunits.12 Among 
the NADPH oxidase subunits, the functional deficiency of 
gp91phox (NOX2), the catalytic subunit of NADPH oxi-
dase, is the more frequent hereditary disorder.12 In a previous 
study, we have shown that youth with hereditary deficiency of 
NOX2 (X-linked Chronic Granulomatous Disease, X-CGD) 
have reduced oxidative stress and enhanced flow-mediated 
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Objective—NADPH oxidase, one of the most important enzymes producing reactive oxidant species, is suggested to play a 
role in experimental atherosclerosis, but its role in human atherosclerosis is still unclear. We hypothesized that a reduced 
activity of NADPH oxidase might be linked to a reduced atherosclerotic burden.
Methods and Results—Thirty-one women carriers of hereditary deficiency of NOX2, the catalytic subunit of NADPH 
oxidase, were matched for sex and age with 31 controls and 31 obese women. Flow-mediated dilation and intima-media 
thickness, 2 surrogate markers of atherosclerosis, serum activity of NOX2, urinary isoprostanes, serum levels of nitrite/
nitrate, and platelet production of isoprostanes and nitrite/nitrate were determined. Compared with controls (5.7±3.0% and 
0.60±0.11 mm), carriers of NOX2 deficiency had higher flow-mediated dilation (9.2±5.0%; P<0.001) and lower intima-
media thickness (0.50±0.11 mm; P=0.002), whereas obese women had lower flow-mediated dilation (3.2±2.1%; P=0.007) 
and higher intima-media thickness (0.71±0.15 mm; P<0.001). Compared with controls, carriers of NOX2 deficiency had 
lower urinary isoprostanes (132.6±87.3 versus 82.3±46.0 pg/mg creatinine; P=0.007) and serum NOX2 activity (24.9±19.3 
versus 12.8±11.9 pg/mL; P=0.004) and higher serum nitrite/nitrate (23.8±7.6 versus 30.5±6.3 µmol/L; P<0.001), whereas 
obese women had higher urinary isoprostanes (132.6±87.3 versus 182.2±84.6 pg/mg creatinine; P=0.008) and serum 
NOX2 activity (24.9±19.3 versus 36.1±18.6 pg/mL; P=0.008) and lower serum nitrite/nitrate (23.8±7.6 versus 12.6±4.2 
µmol/L; P<0.001). Flow-mediated dilation correlated with intima-media thickness (r=–0.433; P<0.001), serum NOX2 
activity (r=–325; P<0.001), and urinary isoprostanes (r=–0.314; P=0.002). Ex vivo study showed that, compared with 
controls, platelets from carriers of NOX2 deficiency had lower isoprostanes (P<0.001) and higher nitrite/nitrate (P<0.001), 
whereas platelets from obese women had higher isoprostanes (P<0.001) and lower nitrite/nitrate (P=0.013).
Conclusion—The study shows reduced atherosclerotic burden in carriers of NOX2 deficiency, suggesting that oxidative 
stress generated by this enzymatic pathway is implicated in human atherosclerosis.  (Arterioscler Thromb Vasc Biol. 
2013;33:406-412.)
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dilation (FMD),13 a surrogate marker of atherosclerosis that is 
predictive of cardiovascular events14 in patients at risk or with 
established atherosclerosis. The fact that NADPH oxidase has 
vasoconstriction properties was confirmed in young adults with 
CGD, who were protected from ischemia-reperfusion injury.15 
Both studies,13,15 however, could not exclude that concomi-
tant therapy, including antibiotics and antifungal prophylaxis, 
influenced the results. To further explore this issue, we decided 
to study women relatives of X-CGD subjects, who were car-
riers of hereditary deficiency of NOX2 and were not under 
antibiotic or antifungal treatment. Therefore, we performed a 
cross-sectional study in which FMD and intima-media thick-
ness (IMT), another surrogate marker of atherosclerosis,16 have 
been measured in women carriers of NOX2 hereditary defi-
ciency, in controls and in obese women, who were associated 
with NOX2 upregulation.13 Herewith, we report for the first 
time that atherosclerosis burden, as assessed by FMD and IMT, 
is reduced in carriers of NOX2 hereditary deficiency.
Materials and Methods
Study Population
We performed a multicenter study in collaboration with the Italian 
Primary Immunodeficiencies Network. Among the women relatives 
of the 60 CGD patients registered in the National database,12 we stud-
ied 31 women carriers of X-CGD who were willing to participate 
in the study. The group of carriers was composed of 23 mothers, 3 
grandmothers, and 5 sisters of X-CGD patients.
Granulocyte function tests were performed to identify X-CGD car-
riers. Carrier detection of X-CGD was performed by searching for a 
mosaic pattern of oxidase-positive and oxidase-negative neutrophils 
in the nitroblue tetrazolium test17 or dihydrorhodamine 123 flow cyto-
metric analysis.18 Genetic analysis of mutations was performed in 18 
X-CGD carriers, as previously described.19 Carriers of NOX2 hereditary 
deficiency were excluded if they were on antibiotic or antifungal treat-
ment or assumed antibiotics or antifungal drugs in the previous month.
Thirty-one women, matched for age and atherosclerotic risk factors, 
were screened from routine visits and used as controls. Furthermore 
we included 31 age-matched obese women; BMI≥30 was used as cut-
off to define obesity. In 2 women aged 9 and 10 years, obesity was 
defined as a BMI≥95th percentile.20 Controls and obese patients were 
recruited from the outpatient clinic of our division at the I Clinica 
Medica of the Sapienza University of Rome.
Subjects were excluded from the study if they had liver disease, 
serious renal disorders (serum creatinine >2.8 mg/dL), cancer, myo-
cardial infarction, unstable angina, acute cerebrovascular disease, 
deep venous thrombosis, or were on treatment with antioxidant 
vitamins.
The study was approved by the Ethical Committee. Each subject 
enrolled gave informed consent to participate in the study.
All participants received a questionnaire to quantitatively estimate 
the level of adherence to Mediterranean diet.21
Type 2 diabetes mellitus was diagnosed according to the American 
Diabetes Association definition.22
Hypercholesterolemia was classified as an low-density lipoprotein 
cholesterol level ≥160 mg/dL.23
Blood Sampling
After overnight fasting (12 hours) and supine rest for at least 10 min-
utes, blood samples were collected in vacutainers between 8 and 9 
am (Vacutainer Systems, Belliver Industrial Estate) and centrifuged 
at 300g for 10 minutes to obtain supernatant, which was stored at 
−80°C until use.
Total cholesterol was measured by routine methods using an enzy-
matic colorimetric method on a Dimension RXL apparatus (Dade 
Behring AG, Switzerland).
Platelet Preparation
To obtain platelet-rich plasma (PRP), blood samples mixed with 
3.8% sodium citrate (ratio 9:1) were centrifuged for 15 minutes at 
180g. To avoid leukocyte contamination, only the top 75% of the PRP 
was collected, according to Pignatelli et al.24
Platelet pellets were obtained by double centrifugation (5 minutes, 
300g) of PRP. Acid/citrate/dextrose (1:7 vol/vol) was added to avoid 
platelet activation during processing; samples were suspended in 
HEPES buffer in presence of 0.1% albumin, pH 7.35 (2×108/mL) 
per mL, and stimulated with or without 0.5 mmol/L arachidonic acid 
or with collagen (7 μg/mL; 10 minutes under stirring conditions). 
Supernatant was separated from cells by centrifugation (5 minutes, 
300g) and stored until analysis.
Urinary 8-Iso-Prostaglandin F2α Assays
Morning urine samples were collected from all participants 
between 7:00 and 9:00 am and stored in 10-mL aliquots at –80°C 
until analysis. Concentration of urinary isoprostane (8-iso-PGF2α) 
was measured by a previously described and validated enzyme 
immuno-assay method.25 Ten microliters of urine was extracted on 
a C-18 solid phase extraction column. The purification was tested 
for recovery by adding a radioactive tracer (tritiated 8-iso-PGF2α; 
Cayman chemical). The eluates were dried under nitrogen, recov-
ered with 1 mL of buffer, and assayed in 8-iso-PGF2α–specific 
enzyme immuno-assay kit (Cayman chemical). Urinary 8-iso-
PGF2α concentration was corrected for recovery and creatinine 
excretion. Values are expressed as pg/mg creatinine. Intraassay 
and interassay coefficients of variation were 2.1% and 4.5%, 
respectively.
Platelet 8-Iso-Prostaglandin F2α Assays
Concentration of 8-iso-PGF2α in supernatant of arachidonic acid (0.5 
mmol/L)-stimulated PRP was measured by a previously described 
and validated enzyme immunoassay method (Cayman chemical, 
MI)25,26 and expressed as pmol/L. Intraassay and interassay coeffi-
cients of variation were 4.4% and 8.8%, respectively.
Nitrite/Nitrate Serum and Platelet 
Level Measurement
A colorimetric assay kit (Tema Ricerca, Italy) was used to determine 
nitric oxide (NO) metabolites, nitrite/nitrate, in the serum and super-
natant of PRP (platelets=3×108/mL) activated with collagen (7 μg/
mL) at 37°C for 15 minutes, as previously described.27 All samples 
were filtered through a 10 000 molecular weight cut-off spin filter 
to remove, in particular, hemoglobin. Intraassay and interassay coef-
ficients of variation were 2.9% and 1.7%, respectively.
Serum and Platelet Soluble NOX2-Derived  
Peptide
Soluble NOX2-derived peptide (sNOX2-dp), a marker of NADPH 
oxidase activation, was detected in serum and platelets supernatant 
by ELISA method, as previously described by Pignatelli et al.28 The 
peptide was recognized by the specific monoclonal antibody against 
the amino acidic sequence (224–268) of the extra membrane portion 
of NOX2. Values were expressed as pg/mL, intraassay and interassay 
coefficients of variation were 5.2% and 6%, respectively, for serum 
and platelets.
C-Reactive Protein
C-reactive protein was measured by commercially available immuno-
assays (Tema Ricerca, Italy). Intraassay and interassay coefficients of 
variation were 9.5% and 9.0%, respectively.
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FMD and IMT
FMD and IMT were performed with a 7.5-MHz linear-array trans-
ducer ultrasound system (SonoScape, China). Ultrasound assessment 
of FMD was investigated according to the recently reported guide-
lines,29 as previously described.30 Brieﬂy, the study was performed 
in a temperature-controlled room (22°C) with the subjects in a rest-
ing supine state between 8 and 10 am. Brachial artery diameter was 
imaged using a 7.5-MHz linear-array transducer ultrasound equipped 
with electronic callipers, vascular software for 2-dimensional imag-
ing, color and spectral Doppler, and internal electrocardiogram; the 
brachial artery was imaged at a location 2 to 5 cm above the antecu-
bital crease; to create a ﬂow stimulus in the brachial artery, a sphyg-
momanometric cuff was placed on the forearm; the cuff was inﬂated 
at least 50 mm Hg above systolic pressure to occlude artery inﬂow for 
5 minutes; all vasodilatation measurements were made at the end of 
diastole. FMD was expressed as a change in poststimulus diameter, 
evaluated as a percentage of the baseline diameter.
The coefficient of variation for FMD measurements, obtained in 3 
separate occasions, was 12.5%.
Longitudinal ultrasonographic scans of the carotid artery were 
obtained on the same day as the studies of the brachial artery reactiv-
ity and included the evaluation of the right and left common carotid 
arteries, 1 cm proximal to the carotid bulb. Three measurements of 
IMT were obtained from the right and left carotid arteries, respec-
tively, and were averaged to determine the mean IMT for both sides 
combined. The coefficient of variation for IMT measurements, 
obtained on 3 separate occasions, was 4.90%.
Statistical Analysis
We used linear mixed-effects models to compare means across 
groups because the subjects in the study were matched by age and 
sex. We used subject-specific random intercepts with clusters of ran-
dom effects identified by the matched triplets (X-CGD carriers, con-
trols, and obese). The group indicators were included as fixed effects. 
Results were further confirmed by nonparametric tests with the rank 
transformation.
Data are presented as mean±SD, unless indicated otherwise. 
Categorical variables were reported as counts (percentage); indepen-
dence of categorical variables was tested by χ2 test. The correlation 
analysis was carried out by Pearson correlation test. Statistical sig-
nificance was defined at P<0.05. Statistical analysis was performed 
with SPSS 18.0 for Windows (SPSS Inc, Chicago, IL).
Sample Size Determination
On the basis of the data emerged by a pilot study, we computed the 
minimum sample size with respect to a 2-sample Student t test, con-
sidering as (1) a relevant difference for FMD values to be detected 
between the X-CGD carriers and controls |δ|≥3%, (2) standard devia-
tions homogeneous between groups SDs=5, and (3) type I error prob-
ability α=0.05 and power 1–β=0.90. This resulted in a minimum 
sample size of 26 subjects for each group. Sample size calculations 
were performed using the software nQuery Advisor, version 5.0, 
(Statistical Solutions, Saugus, MA).
Results
Clinical characteristics of the 3 groups, including X-CGD car-
riers, obese subjects, and controls, are reported in the Table. 
Molecular characterization of 18 X-CGD carriers is reported 
in the Table in the online-only Data Supplement.
As expected, BMI was significantly higher in obese sub-
jects compared with the other 2 groups. We did not observe 
differences in fruit and vegetable dietary intake among the 3 
groups (data not shown). Four X-CGD carriers and 1 control 
were affected by autoimmune diseases. No significant differ-
ence of drug therapy, including statins, angiotensin-convert-
ing-enzyme-inhibitors, corticosteroids, and methotrexate was 
detected among the 3 groups. Furthermore, no difference of 
C-reactive protein serum levels was found in the groups.
At baseline brachial artery diameter did not differ within 
the 3 groups (Table). Compared with controls, X-CGD carri-
ers had significantly higher FMD and lower IMT (Table and 
Figure 1A and 1B). Conversely, obese subjects had lower 
FMD and higher IMT compared with controls (Table and 
Figure 1A and 1B).
Oxidative stress, as assessed by blood sNOX2-dp and uri-
nary isoprostanes, was different among the 3 groups. Thus, 
compared with controls, X-CGD carriers had lower (–50%) 
sNOX2-dp (Table and Figure 2A) and lower (–40%) urinary 
isoprostanes (Table and Figure 2B). Compared with controls, 
obese women had higher sNOX2-dp and urinary isoprostanes 
(Table and Figure 2A and 2B).
NO generation, as assessed by serum nitrite/nitrate, dif-
fered in the 3 groups. Thus, compared with controls, X-CGD 
carriers and obese patients had significantly higher and lower 
serum nitrite/nitrate, respectively (Figure 2C).
A correlation analysis in the overall population showed that 
FMD correlated inversely with sNOX2-dp (R=–325; P=0.001 
and urinary isoprostanes (R=–0.314; P=0.002) and positively 
with IMT (R=–0.433; P<0.001).
Ex vivo study showed that, compared with controls, plate-
let NOX2 and isoprostanes were lower in X-CGD carriers 
and increased in obese women (Figure 3A and 3B); also, 
compared with controls, platelet nitrite/nitrate was higher in 
X-CGD carriers and reduced in obese women (Figure 3C).
Discussion
This study provides the first evidence that in carriers of 
hereditary deficiency of NOX2, the burden of atherosclero-
sis, as assessed by FMD and IMT, is reduced, suggesting a 
role for ROS generated by this enzymatic pathway in human 
atherosclerosis.
Our study hypothesis was that relatives of patients with 
X-CGD could represent an interesting clinical model to 
explore the oxidative stress theory of atherosclerosis because 
they should have less oxidative stress as a consequence of 
incomplete activity of NOX2 and potentially less atheroscle-
rotic burden. Laboratory analyses confirmed ≈50% lowered 
activity of NOX2 in the systemic circulation in X-CGD carri-
ers concidentally with reduced oxidative stress as documented 
by impaired formation of isoprostanes, a reliable marker of 
oxidative stress.31 These findings, which further support the 
key role played by NOX2 in the formation of isoprostanes,13 
were corroborated by an in vitro study showing lower isopros-
tane formation by platelets from X-CDG carriers.
FMD is recognized as a hallmark of systemic atheroscle-
rosis and a useful marker to stratify the risk of cardiovascu-
lar disease in patients at risk,29 or with established clinically 
manifested atherosclerosis.14,32–35 Several experimental studies 
have shown a pivotal role of NADPH oxidase in modulating 
arterial tone.8 This was particularly evident in animal knock-
out models of NADPH oxidase in which an increased arterial 
dilation was detected compared with wild-type.36 A role for 
NADPH oxidase in inhibiting arterial dilation has been sug-
gested also in humans in whom impaired artery dilation was 
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associated with endothelial overexpression of the NADPH 
oxidase subunit p47phox.37
The present study supports and extends previous findings 
in youth,13,15 showing that NOX2 possesses vasoconstriction 
property also in carriers of NOX2 deficiency, who disclosed, 
in fact, enhanced FMD compared with controls.
FMD is prevalently dependent on NO release from endothe-
lium,38 as also suggested by the significant correlation between 
FMD and serum plasma nitroso compounds.39 Oxidative stress 
seems to play a pivotal role in modulating FMD via interfer-
ing with NO bioavailability and biosynthesis.30 In accordance 
with this, we found an inverse correlation between FMD and 
urinary isoprostanes and an overexpression of NO metabolites 
in carriers of NOX2 deficiency, suggesting a link between 
enhanced artery dilation and impaired oxidative stress. We 
recognized that the analysis of serum nitrite/nitrate may be 
influenced by several confounding factors, including intrain-
dividual variability, dietary nitrate uptake, inhalation of atmo-
spheric gaseous nitrogen oxides, salivary formation, and renal 
function.40 However, these findings were supported by ex vivo 
study demonstrating downexpression and overexpression of 
isoprostanes and nitrite/nitrate, respectively, in platelets from 
X-CGD carriers.
Other confounding factors could be reasonably excluded, 
as X-CGD carriers and controls were well matched for age, 
dietary habit, atherosclerotic risk factors, and concomitant 
therapy. A peculiar characteristic of X-CGD carriers was the 
coexistence of lupus-like illness, which is a feature found in 
Table. Clinical Characteristics of X-Chronic Granulomatous Disease (X-CGD) Carriers, Controls, and Obese Patients
X-CGD Carriers (n=31) P Value* Controls (n=31) P Value* Obese Patients (n=31)
Age, y 41.6±14.3 … 41.2±14.3 … 42.6±13.7
Sex 31 women … 31 women … 31 women
Systolic blood pressure, mm Hg 116±6 0.518 117±7 0.013 120±5
Diastolic blood pressure, mm Hg 72±8 0.672 72±10 0.078 75±7
BMI 24.2±4.3 0.692 24.8±5.7 0.002 32.5±4.8
Total cholesterol, mg/dL 199.8±79.7 0.882 196.7±88.7 0.02 244.9±81.3
Triglycerides, mg/dL 83.30±22.56 0.38 88.31±19.34 0.21 93.84±12.65
LDL, mg/dL 153.5±68.5 0.60 145.9±70.7 0.06 187.1±68.1
HDL, mg/dL 52.87±13.27 0.54 50.62±16.0 0.18 45.67±13.87
C-reactive protein, mg/L 2.24±1.0 0.09 1.78±1.1 0.566 1.94±1.1
Current smokers and 11/31 1.0 11/31 1.0 10/31
Cigarettes/d 12.4±4.9 0.812 12.0±3.7 0.921 11.8±5.2
Hypertension 4/31 1.0 4/31 0.919 5/31
Hypercholesterolemia 0/31 0.472 2/31 0.256 6/31
Type 2 diabetes mellitus 0/31 1.0 1/31 0.351 4/31
sNOX2-dp, pg/mL 12.8±11.9 0.004 24.9±19.3 0.008 36.1±18.6
Isoprostanes, pg/mg creatinine 82.3±46.0 0.007 132.6±87.3 0.008 182.2±84.6
NOx, µmol/L 30.5±6.3 <0.001 23.8±7.6 <0.001 12.6±4.2
IMT, mm 0.50±0.11 0.002 0.60±0.11 <0.001 0.71±0.15
FMD, % 9.2±5.0 <0.001 5.7±3.0 0.007 3.2±2.1
Brachial artery diameter (mm) at rest 3.20±0.45 0.263 3.07±0.35 0.08 3.27±0.57
Brachial artery diameter (mm) after 5 min of forearm occlusion 3.49±0.48 0.04 3.24±0.33 0.248 3.38±0.59
Drugs
Statin 0/31 0.472 2/31 0.256 6/31
Angiotensin-converting enzyme inhibitors 4/31 1.0 4/31 1.0 5/31
Corticosteroid therapy 2/31 1.0 1/31 1.0 0/31
Methotrexate 1/31 1.0 1/31 1.0 0/31
Hydroxychloroquine 2/31 0.472 0/31 1.0 0/31
Lupus like-illness
Photosensitive skin rashes 7/31 0.058 1/31 1.0 0/31
Mouth ulcers 3/31 0.605 1/31 1.0 0/31
Joint pains 3/31 0.605 1/31 1.0 0/31
Rectocolitis 1/31 1.0 0/31 1.0 0/31
Hypothyroidism 5/31 0.062 0/31 1.0 0/31
BMI indicates body mass index; FMD, flow-mediated dilation; HDL, high-density lipoprotein; IMT, intima-media thickness; LDL, low-density lipoprotein; and sNOX2-
dp, soluble NOX2-derived peptide.
*Compared with controls.
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≈30% of our population (Table). The prevalence was slightly 
lower than that previously observed,41 but small sample size 
and different inclusion criteria may have accounted for that. 
However, this should not have biased our results, as lupus-like 
illness is associated with accelerated, but not with reduced, 
atherosclerosis.42
The lower IMT in carriers of NOX2 deficiency was another 
important evidence in favor of the reduced atherosclerotic bur-
den in subjects with impaired ROS production. Thus, IMT is 
a noninvasive diagnostic measure of atherosclerosis that cor-
relates with histology and predicts cardiovascular events, 
including myocardial infarction and stroke.43 Of note, IMT 
significantly correlated with FMD, suggesting an interplay 
between the carotid atherosclerotic burden and artery dilatation.
The relationship between NOX2-derived oxidative stress 
and atherosclerotic burden was further corroborated by the 
behavior of oxidative stress and surrogate markers of athero-
sclerosis in obese women. Thus, they showed opposite fea-
tures compared with X-CGD carriers, inasmuch as low FMD 
and high IMT were associated with upregulation of NOX2 and 
urinary isoprostane overexpression. These changes were sup-
ported by an ex vivo study, as platelets from obese women 
disclosed increase of isoprostanes and reduction of NO com-
pared with controls.
Figure 1. The box plots depict the values of flow-mediated dila-
tion (FMD; A) and intima-media thickness (IMT; B), namely the 
minimum and maximum values, the upper and lower quartiles, 
and the median in X-linked Chronic Granulomatous Disease 
(X-CGD) carriers, controls, and obese patients. The median is 
identified by a line inside the box. The length of the box repre-
sents the interquartile range. The extreme lines of the box plot 
depict the maximum and the minimum of the nonoutlier range. 
*P<0.05, **P<0.001.
Figure 2. Box plots of serum levels of soluble NOX2-derived 
peptide (sNOX2-dp; A), urinary isoprostanes excretion (B), and 
serum nitrite/nitrate levels (C) in X-linked Chronic Granulomatous 
Disease (X-CGD) carriers, controls, and obese patients. *P<0.05, 
**P<0.001.
 by MASSIMO BOTTICELLI on January 30, 2013http://atvb.ahajournals.org/Downloaded from 
Violi et al  Low Atherosclerosis in Carriers of NOX2 Deficiency  411
This study has implications and limitations. The interplay 
between NOX2 regulation and 2 surrogate markers of athero-
sclerosis suggests that this enzymatic pathway may be impli-
cated in the process of atherosclerosis via the production of 
ROS. Our findings are apparently in contrast with a recent 
experimental study in mice in which NOX2 overexpression 
was associated with enhanced vascular oxidative stress and 
macrophage recruitment in the vessel wall, but had scarce 
impact in atherosclerotic progression.44 This issue also needs 
to be investigated in humans by prospective analysis of the 
relationship between s-NOX2dp and surrogate markers of ath-
erosclerosis in patients at risk of atherosclerotic disease.
A limitation of the study is the relatively small sample 
size. However, despite CGD being a very rare disease and the 
difficulty of finding carriers of NOX2 hereditary deficiency, 
our samples had adequate power to discover a difference 
between the X-CGD carriers and controls. Another limitation 
is that the study was done in women; therefore, the data can-
not be extrapolated to men. Further study should be performed 
in non–X-linked CGD carriers to see whether NADPH oxi-
dase is implicated in the atherosclerotic process also in men. 
To the best of our knowledge, the relationship between CGD 
and atherosclerosis is still unknown; prospective study should 
be done to see the progression of atherosclerosis in this popu-
lation. This would be useful also to support our speculation 
that reduced IMT and enhanced FMD reflects NOX2-related 
atherosclerotic progression. Finally, we have only indirect evi-
dence suggesting a role for NO in enhancing FMD of X-CGD 
carriers, and further study in human arteries should be done to 
explore such hypothesis.
In conclusion, this study provides evidence that, in humans, 
NOX2 activity is implicated in artery changes that are related 
to human atherosclerosis disease and could provide a new tool 
to follow-up atherosclerotic progression, and eventually its 
clinical complications.
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Table I 
 
gp91phox mutations of 18 X-CGD carriers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carrier 
X-CGD 
cDNA nucleotide change Amino acid change 
1 c.1+?_252+?del p.M1_A84del 
2 c.1+?_252+?del p.M1_A84del 
3 Del ≥550 kb+XK gene Undetectable 
4 c.252G>A r.142_252del 
5 c.388C>T p.R130X 
6 c.1287delT + c.1290delC p.C428fs 
7 c.1123G>T p.E375X 
8 c.1123G>T p.E375X 
9 c.469C>T p.R157X 
10 c.1357T>A p.W453R 
11 c.742dupA p.ile248asnFsX36 
12 p. Arg290Stop p. Arg290Stop 
13 c.937G>A p.Glu309Lys 
14 c.937G>A p.Glu309Lys 
15 c.937G>A p.Glu309Lys 
16 del 32,72 Kb (CYBB gene deleted) Undetectable 
17 del 32,72 Kb (CYBB gene deleted) Undetectable 
18 ca-cc change intron 4 in CYBB gene Unknown 
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